—
C+
C+ The full Closelook — membership. Open the C+ overview

Abivax SA (ABVX.PA) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Abivax SA

ABVX.PA in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Abivax is a clinical-stage biotechnology company based in Paris that develops therapies aimed at calming the body's own immune response in chronic inflammatory disease. Its lead candidate, obefazimod, is in Phase 3 development for ulcerative colitis and in Phase 2b trials for Crohn's disease.
Where it sits in the stack
Abivax holds no seat in Rubin or Halo, so it does not sit inside the AI build-out stack; in Closelook's universe it is simply classed within the Healthcare sector as a biotechnology name.
Who it is priced against
Closelook's peer group places Abivax among other scored Healthcare names — argenx, Eli Lilly, Medpace, BeiGene, UCB, Fisher & Paykel Healthcare and Globus Medical — grouped by sector rather than by shared therapy area.
Why Closelook tracks it
Abivax carries a Closelook score, strongest on valuation and weakest on quality, but it has no index seat and no mentions in the diary's editions.
What the diary watches
The diary watches how the Phase 3 ulcerative colitis programme progresses, since a clinical-stage biotech's read hinges on trial results rather than steady earnings.

Abivax SA (ABVX.PA) trades on the PA exchange in France, classified under Healthcare.

The Closelook company score reads 34/100 composite (momentum 38, quality 1, valuation 54) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for ABVX.PA, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Healthcare · 8 names with week and year-to-date

Peer group

Healthcare

Scored names in the same sector from the Closelook universe.

Compared against ABVX.PA on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sector × region Health care in Europe: +1.1% week · −3.6% month · +0.3% quarter · −6.5% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-16
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Abivax SA (ABVX.PA)?

Abivax SA trades as ABVX.PA on the PA exchange (France) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-18.

Is ABVX.PA in a Closelook index?

Not currently — Abivax SA is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

What is Abivax SA's Closelook composite score?

34 out of 100, with momentum 38, quality 1 and valuation 54 sub-scores, as of 2026-09-18. Scores are Closelook's own research readings, not ratings or investment advice.

Where does ABVX.PA trade against its moving averages?

Mixed moving-average stack: Trades -11.8% vs the 50-day and -8.8% vs the 200-day average, 32.6% below the 52-week high and +55% off the 52-week low; a golden cross printed 55 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Abivax SA do?

Abivax is a clinical-stage biotechnology company based in Paris that develops therapies aimed at calming the body's own immune response in chronic inflammatory disease. Its lead candidate, obefazimod, is in Phase 3 development for ulcerative colitis and in Phase 2b trials for Crohn's disease. Closelook's peer group places Abivax among other scored Healthcare names — argenx, Eli Lilly, Medpace, BeiGene, UCB, Fisher & Paykel Healthcare and Globus Medical — grouped by sector rather than by shared therapy area.

Where does Abivax SA sit in the AI build-out?

Abivax holds no seat in Rubin or Halo, so it does not sit inside the AI build-out stack; in Closelook's universe it is simply classed within the Healthcare sector as a biotechnology name. Abivax carries a Closelook score, strongest on valuation and weakest on quality, but it has no index seat and no mentions in the diary's editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for ABVX.PA, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe